Is HIMS a buy according to AI stock analysis?

HIMS AI stock analysis does not label Hims & Hers an automatic buy. The platform has nearly 2.6 million subscribers and TTM revenue near $2.37 billion, but Q1 2026 United States revenue fell 8%, TTM net income is negative, the FTC filed a lawsuit on July 29, 2026, and the stock trades about 57% below its 52-week high, so the case depends on the FTC outcome, peptide and GLP-1 policy, and a return to profitable growth.

What is the HIMS AI stock forecast?

The HIMS AI stock forecast is a conditional range, not a guaranteed target. Using FY2026 consensus adjusted EPS and a three-year scenario model, the framework points to a bullish area near $75, a base area near $26, and a bearish area near $6 before wider ranges are applied for the FTC case, FDA policy, margin recovery, dilution, and valuation uncertainty.

What technical levels matter for HIMS?

The key HIMS technical levels are support near $26.86 to $27.51, the key support zone near $24.73 to $25.00 from the July 29 low, deeper support near $21 to $24, and resistance near $30.34 to $30.72 from the 200-day and 50-day moving averages, with the 20-day near $32.54 as the next major level. A close below $24.73 would point toward the $21 to $24 zone.

Can AI predict HIMS stock price?

No, AI cannot reliably predict stock prices. AI can organize filings, compare scenarios, calculate valuation ranges, and flag technical and regulatory triggers, but HIMS can move sharply after earnings, FTC or FDA actions, drug supply news, legal developments, or changes in growth-stock multiples.

How should I use this HIMS AI trading strategy?

Use this HIMS AI trading strategy as a research checklist, not as personalized investment advice. Confirm the live price, volume, moving averages, the August 10 Q2 report timing, subscriber trends, gross margin, cash flow, FTC and FDA developments, position size, and invalidation level before making any decision.

What is the biggest risk in HIMS AI stock analysis?

The biggest risk is that the FTC lawsuit and broader regulatory scrutiny, together with the weight-loss supply-chain pivot, turn slower United States revenue and compressed margins into a longer period of losses and cash outflows. Peptide or GLP-1 access changes, short interest near 26.5% of shares outstanding, debt-funded acquisitions, dilution, and CEO voting control all add to the downside.

Why did HIMS stock fall in July 2026?

HIMS shares fell about 19% from the July 10 close of $34.38 to $27.77 on July 31, 2026, as the FTC filed a lawsuit on July 29, 2026 over alleged data sharing, billing, and cancellation practices, and as the market digested a July 23 FDA advisory panel peptide vote that briefly lifted the stock before it gave back the gains. The stock fell about 15% on July 29 and rebounded about 8% on July 30 after the company said it would defend.

Hims & Hers Health, Inc. research snapshot

HIMS AI Stock Analysis

Q: What does the FTC lawsuit mean for HIMS?

The FTC, joined by Utah and Los Angeles County, filed suit on July 29, 2026 alleging Hims & Hers shared sensitive health information with Meta, Snap, and other advertising platforms, charged consumers for prescriptions shortly after intake forms, and made subscriptions difficult to cancel. Hims & Hers denied the claims and said it would vigorously defend. The company had already accrued a $15 million probable loss in Q1 2026 and warned the final cost could be materially higher.

HIMS AI stock analysis as of the August 3, 2026 data cutoff reads Hims & Hers as a scaled consumer health platform facing a harder transition than the subscriber count suggests. The stock closed at $27.77 on July 31, 2026, down about 19% from the $34.38 close on July 10, 2026, with a market capitalization of $6.43 billion computed from 231.46 million shares outstanding and cross-validated with StockAnalysis.com. TTM revenue is about $2.37 billion, but TTM net income turned negative near $13 million as the weight-loss supply-chain pivot, restructuring charges, and a $15 million FTC probable-loss accrual compressed the quarter. The Federal Trade Commission, joined by Utah and Los Angeles County, filed a lawsuit on July 29, 2026 alleging Hims & Hers shared sensitive health information with Meta, Snap, and other advertising platforms, charged consumers for prescriptions shortly after intake forms, and made subscriptions difficult to cancel; the company denied the claims and said it would vigorously defend. On the other side of the ledger, an FDA advisory panel voted on July 23, 2026 to recommend loosening restrictions on a peptide, lifting the stock as much as 13% that day, subscribers reached nearly 2.6 million, rest-of-world revenue grew 969% in Q1 2026, and management kept full-year 2026 guidance at $2.8 billion to $3.0 billion revenue with $275 million to $350 million adjusted EBITDA ahead of the August 10, 2026 Q2 report. The HIMS AI stock forecast is therefore a conditional range tied to the FTC case, FDA peptide and GLP-1 policy, margin recovery, and a return to profitable growth, not a precise price promise.

Current price

$27.77 closing price on July 31, 2026

Market cap

$6.43 billion reported equity value on July 31, 2026

AI score

55 / 100

Rating

High-growth consumer health platform under FTC, margin, and transition pressure

Trend status

Bearish short-term and medium-term setup below the 20-day, 50-day, and 200-day averages after a volatile FTC-driven sell-off, with price just above the 100-day average near $27.51

Data cutoff (updated monthly)

August 4, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: A-level information richness. Hims & Hers has SEC filings including the Q1 2026 Form 10-Q and earnings release, the 2026 proxy statement, current market and technical data from StockAnalysis.com and Barchart, analyst forecasts from S&P Global, and primary regulatory documents including the FTC press release and complaint. The August 3, 2026 refresh re-fetched and re-validated the key figures: the $27.77 close, $6.43 billion market cap, TTM revenue near $2.37 billion, Q1 2026 results, the July 29, 2026 FTC lawsuit, the July 23, 2026 FDA advisory panel peptide vote, and the balance sheet figures of $750.9 million cash and short-term investments, $974.1 million convertible senior notes, and $446.2 million stockholders equity as of March 31, 2026, which matched across StockAnalysis.com, the Q1 2026 earnings release, and the Q1 2026 Form 10-Q. Q2 2026 results are scheduled for August 10, 2026, so the newest reported quarter remains Q1 2026.
bias Check: The main AI bias risk is repeating the subscriber and telehealth growth story while under-weighting the FTC lawsuit, the Q1 United States revenue decline of 8%, lower revenue per subscriber of $80 versus $85, gross margin compression to 65%, the TTM net loss, and short interest near 26.5% of shares outstanding. The reverse check asks whether the July 29 sell-off and the July 30 rebound have fully priced the regulatory risk, whether the FDA peptide vote is being treated as a certainty, and whether the valuation can recover if the August 10 report or the FTC case disappoints.
ai Confidence: High for company-reported revenue, subscribers, cash flow, guidance, ownership data, the FTC complaint, and analyst consensus through the latest filings and market data. Medium for forward valuation, normalized earnings, and technical levels because Q1 results include one-time restructuring effects, Q2 earnings arrive August 10, and the market can move sharply on FDA, FTC, and litigation headlines.
investment Certainty: Low to medium. The platform, subscriber base, and international expansion are real, but the current case depends on the outcome of the FTC lawsuit, peptide and GLP-1 regulatory developments, margin recovery, and a return to GAAP profitability, all of which are uncertain.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	Hims & Hers combines telehealth consultations, recurring prescription products, diagnostics, fulfillment, and consumer health content in a direct-to-consumer platform with nearly 2.6 million subscribers and TTM revenue near $2.37 billion, but TTM net income is negative as the business absorbs the weight-loss supply-chain pivot.	Medium-high
Moat	Brand recognition, subscriber data, recurring workflows, provider and pharmacy relationships, and a growing multi-specialty platform create a useful moat, but much of the care and fulfillment infrastructure can be competed away by telehealth, pharmacy, retailer, and direct pharmaceutical channels.	Medium
Management	Co-founder and CEO Andrew Dudum holds 87.73% of total voting power as of April 16, 2026, so alignment and control are both high. The team has acted decisively on products, acquisitions, and buybacks, but the FTC dispute, the Chief Accounting Officer departure announced July 17, 2026, and debt-funded acquisitions raise governance and capital allocation questions.	Medium
Financial trend	FY2025 revenue rose 59% to $2.35 billion with $300.0 million operating cash flow, but Q1 2026 revenue growth slowed to 4%, United States revenue fell 8%, gross margin fell to 65%, adjusted EBITDA dropped to $44.3 million, and GAAP net income was a $92.1 million loss, leaving TTM net income near a $13 million loss.	High
Valuation	At $27.77, the stock trades at 2.71x TTM sales, 32.51x forward PE, 40.84x FY2026 consensus adjusted EPS, and 80.64x TTM free cash flow using exact financial_rigor.py inputs. The multiple is not a bargain even after the pullback unless EPS and margins recover as consensus expects.	High for reported inputs
Technical trend	Price closed at $27.77 on July 31, below the 20-day average near $32.54, the 50-day near $30.72, and the 200-day near $30.34, and just above the 100-day near $27.51, with 14-day RSI near 41.63 and very high volatility.	Medium
Risk level	Risk is very high because the FTC lawsuit, FDA peptide and GLP-1 policy, billing and privacy scrutiny, gross margin, leverage from convertible notes, international integration, dilution, short interest near 26.5% of shares, and CEO voting control can all affect the thesis.	High
AI confidence	Descriptive confidence is high for audited and company-reported numbers, the FTC complaint, and analyst consensus, while normalized earnings and the scenario model remain assumption-sensitive around the August 10 report.	High data confidence
Investment certainty	HIMS may compound if it turns subscriber scale into durable retention, better unit economics, and profitable international growth, but the FTC case, regulatory swings, and transition costs mean the current evidence does not support high certainty.	Low to medium

HIMS AI stock forecast

HIMS AI Stock Forecast Scenarios

The HIMS AI stock forecast uses the July 31, 2026 close of $27.77 and the FY2026 consensus adjusted EPS estimate of $0.68 as a normalized starting point because GAAP earnings are distorted by the weight-loss supply-chain pivot, restructuring charges, and the FTC matter. A three-year model using exact financial_rigor.py arithmetic produced an optimistic output near $74.6, a central output near $25.9, and a pessimistic output near $5.9. The page shows broader ranges around those outputs because actual results can differ materially depending on the FTC lawsuit, FDA peptide and GLP-1 policy, margin recovery, international integration, and execution.

Bullish case

$55 to $75

More likely if the FTC matter resolves without material business change, the FDA loosens peptide restrictions, branded GLP-1 demand scales, Q2 and full-year revenue land near the top of guidance, gross margin recovers, international acquisitions integrate well, and normalized EPS compounds near 40% with a 40x exit multiple.

Base case

$22 to $32

More likely if 2026 revenue reaches the middle of the $2.8 billion to $3.0 billion guide, the FTC lawsuit creates legal cost and distraction but limited revenue impact, margin recovery is gradual, and normalized EPS compounds near 15% with a 25x exit multiple, which would leave the stock near current levels.

Bearish case

$4 to $9

More likely if the FTC lawsuit escalates or expands, peptide or GLP-1 access narrows, United States demand stays weak, gross margin keeps falling, international acquisitions add dilution and debt pressure, and normalized EPS declines near 10% a year with a 12x exit multiple.

HIMS AI technical analysis

HIMS AI Technical Analysis

HIMS AI technical analysis was bearish in the short and medium term as of the July 31, 2026 close. Price at $27.77 was below the 20-day SMA near $32.54, the 50-day SMA near $30.72, and the 200-day SMA near $30.34, and marginally above the 100-day SMA near $27.51. The 14-day RSI was about 41.63, the 14-day ADX about 19.26, and 14-day historical volatility about 115.8%, so the stock is in a high-volatility range after the July 23 peptide pop and the July 29 FTC-driven drop.

Level	Value	Why it matters
Current price	$27.77	July 31, 2026 closing price used as the data cutoff market reference; after hours traded near $27.60.
5-day moving average	$27.87	Barchart reported the 5-day moving average near $27.87, just above the July 31 close, so near-term momentum is flat.
Near support	$26.86 to $27.51	The July 31 low and the 100-day SMA form the first pullback area.
Key support	$24.73 to $25.00	The July 29 intraday low and close, the FTC lawsuit sell-off zone, are the main downside reference.
Deeper support	$21.00 to $24.00	May 2026 lows and the $21 Morgan Stanley target mark the deeper support zone above the 52-week low of $13.74.
Near resistance	$28.94 to $30.24	The July 31 high and the July 27 close are the first overhead references.
Resistance cluster	$30.34 to $30.72	The 200-day and 50-day SMAs form the main overhead zone for a recovery attempt.
Major resistance	$32.54 to $34.38	The 20-day SMA and the July 10 close represent the major near-term resistance, with the July 6 high of $39.05 above that.
Moving averages	20-day $32.54, 50-day $30.72, 100-day $27.51, 200-day $30.34	Price was below the 20-day, 50-day, and 200-day averages and just above the 100-day average at the cutoff, a weak short-term and medium-term setup.
Momentum	Weak, RSI near 41.63, ADX near 19	The reported 14-day RSI near 41.63 and ADX near 19.26 signal a weak, ranging market rather than a strong trend in either direction.
Volume	12.5M shares on July 31; 20-day average near 14.3M	The July 29 and July 30 sessions printed 28.7M and 16.6M shares, so the rebound after the FTC drop happened on above-average volume while the July 31 close cooled.
Volatility	Very high, 14-day historical volatility near 116%	HIMS is sensitive to FTC and FDA actions, peptide and GLP-1 headlines, earnings, short covering, and growth-stock multiple swings, with Barchart reporting 14-day historical volatility near 115.8%.
Invalidation	Daily close below $24.73, then $21.00	A break below the July 29 low would open a test of the $21 to $24 zone, and a close below that area would point toward the 52-week low near $13.74. A recovery needs a close back above the $30.34 to $30.72 zone.

HIMS AI trading strategy

HIMS AI Trading Strategy Framework

The HIMS AI trading strategy below is a rules-based research framework, not personalized advice. It links technical levels to the FTC lawsuit, FDA peptide and GLP-1 policy, subscriber growth, United States revenue, gross margin, cash flow, the August 10 Q2 report, and acquisition integration.

Trend-following setup

Watch for a close back above $30.34 to $30.72 on volume near or above the 20-day average while the August 10 Q2 report confirms revenue acceleration, subscriber retention, a stable margin path, and a contained FTC and peptide story.

A failed recovery followed by a close below $28.94 should reduce confidence. A close below $24.73 weakens the setup, especially if the FTC complaint expands or guidance is cut.

Mean-reversion setup

If HIMS pulls back toward $24.73 to $27.51 without a worse FTC outcome, adverse peptide or GLP-1 policy, or a guidance cut, compare the price with subscriber growth, cash flow, Q2 guidance, and the value of the international platform before acting.

Do not treat a technical bounce as benign while the FTC lawsuit, short interest near 26.5% of shares outstanding, margin pressure, or debt-funded acquisitions are unresolved.

Fundamental monitor

Track the FTC case, FDA peptide and GLP-1 decisions, United States and rest-of-world revenue, subscribers, monthly revenue per average subscriber, retention, gross margin, adjusted EBITDA, free cash flow, cash, convertible debt, share count, the August 10 Q2 report, and Eucalyptus integration.

Position sizing should reflect that HIMS is a high-volatility healthcare growth stock with very elevated short interest. The 2030 targets of at least $6.5 billion revenue and $1.3 billion adjusted EBITDA are management targets, not guaranteed outcomes.

Investment research summary

Four-master Research Compression

Business essence

Customers pay Hims & Hers for lower-friction access to health consultations, prescriptions, diagnostics, and recurring treatment plans across sexual health, dermatology, mental health, weight loss, and women's health. The economic engine is a subscription workflow that combines consumer acquisition, provider access, product fulfillment, and follow-up data, with nearly 2.6 million subscribers and TTM revenue near $2.37 billion.

Moat

The strongest moat is the combination of brand, recurring customer relationships, first-party health and treatment data, provider and pharmacy operations, and cross-selling across specialties. Switching costs are real but limited because consumers can use other telehealth providers, pharmacies, retailers, or direct pharmaceutical channels.

Munger risk inversion

The thesis fails if the FTC lawsuit or other regulators restrict privacy, billing, or marketing practices, peptide or GLP-1 access narrows, United States growth stays weak, margin recovery stalls, or acquisitions add dilution and debt faster than they create durable cash flow. The main question is whether HIMS can return to profitable growth while managing regulatory, legal, and margin risk.

Management

Andrew Dudum is co-founder, CEO, chairman, and a major Class V holder with 87.73% of total voting power as of April 16, 2026. The team has acted decisively on products, acquisitions, technology, and share repurchases, but the FTC dispute, the Chief Accounting Officer departure announced July 17, 2026, and heavy CEO control raise governance and capital allocation questions.

Industry trend

Consumer healthcare is moving toward digital intake, telehealth, at-home diagnostics, personalized treatment, and direct access to branded medicines, and HIMS sits in that transition. The July 23, 2026 FDA advisory panel vote to recommend loosening peptide restrictions is a potential tailwind, while the July 29, 2026 FTC action shows how quickly the regulatory environment can shift for health data, billing, and subscription businesses.

Valuation and margin of safety

At $27.77, HIMS traded at 2.71x TTM sales, 32.51x forward PE, 40.84x FY2026 consensus adjusted EPS, and 80.64x TTM free cash flow using exact financial_rigor.py inputs, with net debt near $381 million after convertible notes and lease obligations. Revenue growth alone is not enough. Margin of safety improves if the company converts subscriber scale into durable free cash flow and normalized EPS after the transition, and it weakens if the FTC case, margin compression, or a longer transition period erodes confidence.

Source-backed data

HIMS Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
HIMS closing price	$27.77 on July 31, 2026, with an after-hours print near $27.60	StockAnalysis.com real-time quote	August 3, 2026
Market capitalization	$6.43 billion, computed as $27.77 x 231.46 million shares outstanding, 0.04% below the reported figure	StockAnalysis.com quote and share statistics	August 3, 2026
Q1 2026 revenue and subscribers	$608.1 million revenue up 4%, 2.584 million subscribers up 9%, and monthly revenue per average subscriber of $80 down 6%	Hims & Hers Q1 2026 results	August 3, 2026
Q1 2026 revenue geography	$529.9 million United States revenue, down 8%, and $78.2 million rest-of-world revenue, up 969%	Hims & Hers Q1 2026 results	August 3, 2026
Q1 2026 profitability	$92.1 million net loss, 65% gross margin, $44.3 million adjusted EBITDA, and $53.0 million free cash flow, including $33.5 million of restructuring charges and a $15.0 million FTC probable-loss accrual	Hims & Hers Q1 2026 results	August 3, 2026
FY2025 financial history	$2.348 billion revenue, $128.37 million net income, and 74% gross margin	SEC 2025 Form 10-K and StockAnalysis.com financials	August 3, 2026
FY2025 cash generation	$300.0 million operating cash flow and $57.4 million company-defined free cash flow; StockAnalysis.com reports $73.96 million standardized free cash flow because its formula excludes purchases of intangible assets	SEC FY2025 earnings release and StockAnalysis.com cash flow statement	August 3, 2026
TTM financials	$2.37 billion TTM revenue, $1.70 billion TTM gross profit, a $30.61 million TTM operating loss, and a $13.24 million TTM net loss through March 31, 2026	StockAnalysis.com financials	August 3, 2026
Q1 2026 liquidity and debt	$222.3 million cash, $528.6 million short-term available-for-sale investments, $974.1 million convertible senior notes, and $446.2 million stockholders equity at March 31, 2026	Hims & Hers Q1 2026 Form 10-Q	August 3, 2026
FTC lawsuit	Filed July 29, 2026 with Utah and California by and through Los Angeles County Counsel, alleging the company shared sensitive health information with Meta, Snap, and other advertising platforms, charged for prescriptions shortly after intake forms, and made cancellation difficult; commission vote 2-0, filed in the Northern District of California	FTC press release	August 3, 2026
Company FTC response and market reaction	Hims & Hers denied the claims, called the lawsuit unsupported after a nearly three-year investigation, and said it would vigorously defend; shares fell about 15% on July 29, 2026 and rose about 8% on July 30, 2026	CNBC and StockAnalysis.com historical prices	August 3, 2026
FDA peptide advisory vote	On July 23, 2026, an FDA advisory committee voted to recommend loosening restrictions on a peptide, and HIMS shares rose as much as 13% that day	Reuters and TipRanks via StockAnalysis.com news feed	August 3, 2026
Q2 2026 earnings date	August 10, 2026, after market close	Hims & Hers investor release	August 3, 2026
2026 management guidance	$2.8 billion to $3.0 billion revenue and $275 million to $350 million adjusted EBITDA, with Q2 2026 revenue guidance of $680 million to $700 million	Hims & Hers Q1 2026 results	August 3, 2026
Analyst consensus	Hold with an average target of $29.23 across 15 analysts, low $21 and high $40, median $27	StockAnalysis.com forecast	August 3, 2026
Recent analyst target updates	Morgan Stanley Hold $21 on July 30, Bank of America Hold $37 to $30 on July 30, Citi Hold $35 on July 30, and Truist Hold $27 on July 29, 2026	StockAnalysis.com forecast and analyst ratings	August 3, 2026
FY2026 and FY2027 consensus estimates	FY2026 revenue $3.0 billion with adjusted EPS $0.68, FY2027 revenue $3.93 billion with adjusted EPS $1.30	StockAnalysis.com forecast financial forecast	August 3, 2026
Technical references	5-day SMA near $27.87, 20-day SMA near $32.54, 50-day SMA near $30.72, 100-day SMA near $27.51, 200-day SMA near $30.34, 14-day RSI near 41.63, 14-day ADX near 19.26, 14-day historical volatility near 115.79%	Barchart and StockAnalysis.com technical snapshots	August 3, 2026
July 31 volume and average volume	12.5 million shares on July 31, 2026, with 20-day average volume near 14.3 million shares	StockAnalysis.com historical prices	August 3, 2026
Short interest	61.41 million shares short, 26.53% of shares outstanding, 3.71 days to cover	StockAnalysis.com statistics short selling	August 3, 2026
52-week range and performance	52-week range $13.74 to $70.43, down 57.62% over the trailing 52 weeks, beta 2.43	StockAnalysis.com quote and statistics	August 3, 2026
Management control	Andrew Dudum reported 87.73% of total voting power as of April 16, 2026	Hims & Hers 2026 proxy statement	August 3, 2026
Eucalyptus acquisition	Completed June 2, 2026; transaction consideration can include cash, deferred payments, and earn-outs	Hims & Hers acquisition completion release	August 3, 2026
June 2026 convertible notes	$350 million upsized convertible senior notes offering announced to support international expansion and AI-driven platform investment	Hims & Hers investor release	August 3, 2026
Valuation math	2.71x TTM sales, 32.51x forward PE, 40.84x FY2026 consensus adjusted EPS, 80.64x TTM free cash flow, 48.72x FY2025 basic EPS, and 111.98x FY2025 company-defined FCF per share from financial_rigor.py	financial_rigor.py exact arithmetic using SEC, StockAnalysis.com, and consensus inputs	August 3, 2026

Frequently Asked Questions

Read the CRWD AI stock analysis View the OSCR AI stock forecast Explore AI Stock Picker Generate an AI trading strategy

This HIMS AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 3, 2026 and can be wrong. Market prices and technical levels may change after publication.